This interview will focus on the current treatment landscape and the prescribing patterns of Lexicon's dual SGLT1 and SGLT2 inhibitor Inpefa (sotagliflozin) in patients with heart failure
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Q4 #1 Speaking with a Cardiologist who has experience treating heart failure patients to discuss the standard of care and the use of Inpefa (sotagliflozin).
Ticker(s): LXRXWho's the expert?
Institution: BJC Medical Group
- Board-Certified in Interventional Cardiology and Cardiovascular Disease
- interested in renal denervation and hopes to perform the procedure in the future once it’s FDA approved
- treats many patients with resistant hypertension and is familiar with the Spyral RDN system
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
